MTNB Matinas BioPharma Holdings, Inc. Quick Ratio

This daily price chart for Matinas BioPharma (MTNB), where the coefficient is 0.88, reflects risks stemming from a liquidity shortage and high testing costs in the absence of sales. However, the business relies on its authority in developing safe drug delivery systems. The company's success is based on attracting top chemists through flexible management and a long-term option system.

Portfolio managers are closely examining the operating model of Matinas BioPharma (MTNB) through the lens of solvency. This indicator measures the ability to settle short-term debts using only cash and accounts receivable, completely ignoring illiquid inventory. Analyzing the quick ratio allows for an assessment of the financial reserve necessary to maintain costly partnerships for the development of oral drug formulations. The stability of this metric confirms the company's fundamental resilience.